$365.81
Insights on Argenx Se
Revenue is down for the last 2 quarters, 407.43M → 401.00M (in $), with an average decrease of 1.6% per quarter
Netprofit is up for the last 2 quarters, -99.31M → -61.59M (in $), with an average increase of 61.2% per quarter
In the last 1 year, Novo Nordisk A/s has given 56.5% return, outperforming this stock by 68.0%
In the last 3 years, Novo Nordisk A/s has given 231.2% return, outperforming this stock by 198.5%
0.45%
Downside
Day's Volatility :3.03%
Upside
2.58%
10.41%
Downside
52 Weeks Volatility :40.49%
Upside
33.58%
Period | Argenx Se | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -7.48% | 0.5% | 0.0% |
6 Months | -25.24% | 14.1% | 0.0% |
1 Year | -11.52% | 11.9% | 0.0% |
3 Years | 32.67% | 18.7% | -20.0% |
Market Capitalization | 22.2B |
Book Value | $69.22 |
Earnings Per Share (EPS) | -5.69 |
PEG Ratio | 0.0 |
Wall Street Target Price | 479.59 |
Profit Margin | -22.59% |
Operating Margin TTM | -22.21% |
Return On Assets TTM | -6.85% |
Return On Equity TTM | -8.54% |
Revenue TTM | 1.5B |
Revenue Per Share TTM | 1.0 |
Quarterly Revenue Growth YOY | 79.4% |
Gross Profit TTM | -251.8M |
EBITDA | -304.2M |
Diluted Eps TTM | -5.69 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.94 |
EPS Estimate Next Year | 3.37 |
EPS Estimate Current Quarter | -0.86 |
EPS Estimate Next Quarter | -0.82 |
What analysts predicted
Upside of 31.1%
Sell
Neutral
Buy
Argenx Se is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Argenx Se | 2.06% | -25.24% | -11.52% | 32.67% | 187.84% |
Moderna, Inc. | 30.29% | 68.31% | 6.04% | -16.69% | 488.05% |
Regeneron Pharmaceuticals, Inc. | 9.88% | 22.54% | 31.41% | 90.29% | 224.65% |
Novo Nordisk A/s | 7.45% | 27.32% | 56.5% | 231.22% | 458.15% |
Vertex Pharmaceuticals Incorporated | 13.15% | 24.76% | 31.15% | 107.42% | 168.64% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Argenx Se | NA | NA | 0.0 | -2.94 | -0.09 | -0.07 | NA | 69.22 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.04 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.57 | 28.57 | 1.46 | 44.2 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.03 | 46.03 | 2.36 | 3.47 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 28.58 | 28.58 | 0.53 | 17.11 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Argenx Se | Buy | $22.2B | 187.84% | NA | -22.59% |
Moderna, Inc. | Buy | $50.8B | 488.05% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $106.7B | 224.65% | 28.57 | 29.45% |
Novo Nordisk A/s | Buy | $593.5B | 458.15% | 46.03 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $113.7B | 168.64% | 28.58 | 39.46% |
FMR Inc
T. Rowe Price Associates, Inc.
Artisan Partners Limited Partnership
Capital World Investors
HHG PLC
venBio Select Advisor LLC
Argenx Se’s price-to-earnings ratio stands at None
Read MoreArgenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.
Organization | Argenx Se |
Employees | 1148 |
CEO | Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc. |
Industry | Health Technology |
Ppg Industries Inc.
$365.81
-2.87%
Microsectors Energy 3x Inverse Leveraged Notes Due January 29 2043
$365.81
-2.87%
Core Msci Total Intl Stk Ishares Etf
$365.81
-2.87%
Wec Energy Group, Inc.
$365.81
-2.87%
Paychex, Inc.
$365.81
-2.87%
Celanese Corporation
$365.81
-2.87%
Restaurant Brands International
$365.81
-2.87%
Rio Tinto Plc
$365.81
-2.87%
Thomson Reuters Corp.
$365.81
-2.87%